Daiichi Sankyo traded at ¥2,729 on the overnight PTS, ¥20 above the TSE closing price. According to the earnings summary, revenue for the first quarter of the fiscal year ending March 2027 rose to ¥574.7 billion on growth in core products such as Enhertu, while operating profit fell to ¥85.1 billion and quarterly profit attributable to owners of the parent fell to ¥68.6 billion.
The overnight PTS trading price was ¥2,729, up ¥20 from the previous day. The opening price was ¥2,704, the high was ¥2,729.9, the low was ¥2,704, trading volume was 6,000 shares, and trading value was ¥16.318 million, according to reports. Overnight trading refers to the overnight session on J-Market operated by JapanNext Securities, and the change versus the TSE closing price is also shown.
According to the earnings summary, revenue for the first quarter of the fiscal year ending March 2027 was ¥574.7 billion, up year on year, driven by growth in core products such as Enhertu and the weaker yen. Operating profit fell to ¥85.1 billion due mainly to a sharp increase in non-core expenses, while quarterly profit attributable to owners of the parent declined to ¥68.6 billion.
The next earnings announcement is expected in late October 2026. The analysis also states that performance over the past 12 quarters has shown a somewhat weak trend. Key points to monitor going forward include overseas penetration and expansion of indications, progress in regulatory reviews of products under development, and drug price trends.
Related information accompanying the earnings coverage includes columns on dividends, shareholder benefits, and AI-based commentary on share price movements, but the article does not present specific investment recommendations or forecasts for price gains.